A REVIEW OF GW7647

These trials confirmed clinically considerable pharmacokinetic interactions [seven] characterized by a lessen in the clearance on the anticancer drug and as a result elevated exposure. The interpretation of subsequent stage II and III medical trials was intricate as it was impossible to administer a similar dose of chemotherapy within the presence